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Purpose: Continuous flow (CF) left ventricular assist devices (LVAD) support 
diminishes vascular pressure pulsatility. Despite its recent clinical success and 
reliability, CF LVAD support has been associated with adverse events including 
gastrointestinal bleeding, aortic valve insufficiency, and hemorrhagic strokes. To 
overcome these limitations, we have developed flow/RPM modulation algorithms 
to provide vascular pulsatility using a CF LVAD. 
 
Methods: The effects of timing and synchronizing the CF LVAD flow/RPM 
modulation to the native ventricle, modulation amplitude, and modulation widths 
were studied on the native ventricle and vasculature using computer simulation, 
mock loop, and animal model studies. A total of over 100 combinations of flow 
modulation algorithms to modulate CF LVAD flow/RPM were tested for partial 
and full LVAD support modes.  
 
Results: Modulation of CF LVAD flow/RPM resulted in an increased arterial 
pressure pulsatility of up to 50 mmHg during asynchronous modulation and 20 
mmHg during synchronous modulation. Synchronous CF LVAD RPM modulation 
allowed for a range of reduced left ventricular external work (LVEW) as 
compared to un-modulated CF LVAD support conditions. Full support co-
vii 
 
pulsation (high RPM during systole, low RPM during diastole) created greater 
pulse pressures as compared to counter pulsation (high RPM during diastole, low 
RPM during systole). However, all full support modulation timings yielded higher 
pulse pressure than normal full support CF LVAD flow at low ventricular 
contractilities. Importantly, reduction in LVEW and increase in pulsatility may be 
adjusted to user-defined values while maintaining the same average CF LVAD 
flow rate.  
 
Conclusions: These LVAD flow/RPM modulations may reduce the incidence of 
adverse events associated with the CF LVAD therapy by increasing vascular 
pulsatility and reducing vascular impedance. Further, these methods of CF LVAD 
flow/RPM modulation may enable tailored unloading of the native ventricle to 
provide rest and rehabilitation (maximal unloading to rest followed by gradual 
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Approximately 80 million Americans suffer from cardiovascular disease, which 
has become the leading cause of death among both men and women in the 
United States. Cardiovascular disease accounts for over 550,000 deaths per 
year and led to a projected $450 billion in healthcare costs in 2009. Of these 80 
million, six million will develop chronic heart failure (Figure 1) [1]. Furthermore, 
one-year mortality rates for New York Heart Failure Association Class IV patients 
exceed 60%.  
 
Figure 1: Chronic heart failure rates in the United States continue to 










In congestive heart failure (CHF), the heart is unable to deliver the necessary 
rate of sufficient blood, oxygen, and metabolites for the metabolic demands of 
organs and tissues. CHF can occur both acutely and chronically depending on 
the etiology of the disease. A patient can develop CHF abruptly in cases such as 
sudden onset of fluid overload, valvular dysfunction or a severe myocardial 
infarction. Chronically, heart failure can result due to persistent elevated work 
requirements of the heart which may be secondary to valve disease, 
hypertension, or ischemia among others. Further, reduced contractility can occur 
due to weakening of the cardiomyocytes or stiffening of the myocardium during 





During progression of CHF, mechanisms assist the heart and body to adapt to 
meet metabolic needs. Myocardial contraction increases as diastolic volume 
increases via increase in myosin-actin interaction, as described by the Frank-




stages of heart failure in efforts to maintain necessary cardiac output. However, 
this can create an additive effect that eventually results in worsening heart failure. 
Additionally, the autonomic nervous system can release norepinephrine to 
increase the frequency of heart contractions. Similarly, the renin-angiotensin-
aldosterone pathway along with release of natriuretic peptide results in changes 
in filling volumes and pressures. Early symptoms of left-sided failure are often 
associated with pulmonary congestion and edema. Activation of the renin-
angiotensin-aldosterone system, caused by inadequate kidney perfusion, can 
lead to an increase in pulmonary vessel pressure and subsequent onset of 
hypoxia[3]. Furthermore, diminished arterial pressure pulsatility has been shown 





The gold-standard treatment for these patients, cardiac transplantation, has a 
50% 10-year survival rate. While transplantation significantly improves the 
patient’s quality of life[6], patients are required to take immunosuppressant 
medications, weakening their immune system. The frequency of available donor 
hearts limits the number of transplanted patients with less than 4,000 cardiac 




past five years there has been no significant increase in transplant rates, which 
suggests this therapy is not a practical long-term solution for the majority of CHF 
patients (Figure 2). Thus, these untransplanted patients are viable candidates for 
alternative therapy[7].  
 
 
Figure 2: The number of heart transplant per year has not increased, and in 
recent history has actually been decreasing in frequency [7]. 
 
Alternatives to cardiac transplantation include medicinal therapies, techniques, 
and devices, which slow the deterioration of heart function and improve patients’ 
functional status. Rest and relaxation of the cardiac muscle has long been the 
underlying theme of heart failure treatment. Originally, patients were sequestered 
to bed rest and limited mobility. Thus, while waiting for transplant or other therapy, 
the sick patients had a much-reduced quality of life from a combination of their 
disease and their treatment, including being bed-ridden and a forced reduction in 
their daily activities. Currently, medicinal therapies seek to reduce the afterload 




administration of diuretics, angiotensin-converting enzyme (ACE) inhibitors, 
angiotensin II receptor blockers, beta-blockers, and others[8]. Yet, perhaps the 




Development of mechanical circulatory support 
 
In 1964, The National Heart Institute established the Artificial Heart Program. The 
following year, the National Institute of Health requested $40 million for the 
upstart of the program. Dr. Denton Cooley implanted the first American artificial 
heart in 1969 as a bridge to transplant. The device supported the patient for 64 
hours till a heart could be found, however the patient survived little more than 30 
hours post-transplant. Later that year, an NHI sponsored group on Cardiac 
Replacement concluded that left ventricular assist devices (LVAD) would be a 
promising area of research due to the current engineering short comings in 
developing a completely artificial heart (i.e. TETS system, biocompatibility issues, 
durability)[9]. 
 
In the three decades following the suggestion to explore the development of 




original artificial heart programs. Specifically, engineers had sufficiently answered 
the issues of material biocompatibility and the life threatening driveline infections 
to make LVAD a legitimate therapy for end-stage heart failure patients. The use 
of textured titanium surface, titanium alloys, polymers and other biocompatible 
materials allowed for chronic device implantation without the risk of a clinically 
significant reaction[10]. Further, experience with cannula designs and drivelines 
resulted in improvements of the percutaneous lines that exit the body and 
resulted in reducing the infection risk[11].    
 
The majority of devices developed during these three decades were categorized 
by their pulsatile flow that mimicked the native heart. The devices used 
membranes that were actuated, using a fill and eject cycle, similar to the native 
ventricle. The first generation of implantable pulsatile flow LVADs (Thoratec IVAD 
and HeartMate XVE, Worldheart Novacor) weighed up to 1kg and took up to one 
half liter (volume) of space inside the implanted patient abdominal cavity. The 
size restriction excluded smaller males, and most females as candidates for 
therapy [12]. These pulsatile flow mechanical circulatory support devices were 
effective in providing long-term (> 6 months) support. 
 
However, the durability of the pulsatile pumps was sub-optimal (~18 months). 




second year of support, with the most common failing mechanism being inflow 
valve insufficiency [13]. The challenge of mechanical circulatory assist device 
durability was addressed with the introduction of smaller, compact design, 
second-generation blood pumps. Rotary pumps, which produce continuous, non-
pulsatile flow, have reduced the number of moving parts to a single impeller/ 
rotor. The reduction in moving parts has resulted in clinical experience 
demonstrating improved durability and lower power consumption [14].  
 
Left ventricular assist device (LVAD) implantation has increased in popularity as 
a therapeutic measure for bridging to transplantation in patients with end-stage 
heart failure, and is gaining wider clinical acceptance as destination therapy in 
patients ineligible for transplantation [14-16].  Further, there is hope that these 
devices can be operated in such a way as to promote myocardial recovery. 
During support they have been shown to be capable of partially reversing many 
of the genetic, functional, and morphological hallmarks of the failing heart[17-23], 
in addition to allowing device removal without transplantation in a small fraction 
of patients[24, 25].  Recent evidence indicates that while there are differences in 
the magnitude of unloading between pulsatile flow (PF) and continuous flow (CF) 
pumps, both are capable of achieving normalization of some cellular damage 
markers[26], and continuous flow pumps appear to be just as effective if not 




Furthermore, support in patients who do not meet transplant criteria, destination 
therapy, has shown longer survival in continuous flow as compared to pulsatile 
flow devices[14]. Given the apparent similarity in the survival benefit offered to 
heart failure patients by these devices, CF LVAD has gained greater acceptance 
as they have fewer moving parts, higher mechanical reliability[28], and are 
considerably smaller, minimizing thrombogenic surface area and enabling 
implantation in smaller adults as compare to their pulsatile counterparts. 
 
Amidst the growing popularity of CF LVAD, however, there remain unanswered 
questions regarding the long-term physiological effects of CF LVAD support. CF 
LVAD significantly diminish vascular pressure pulsatility compared to PF LVAD 
and anecdotal reports have indicated the development adverse events including 
gastrointestinal bleeding, hemorrhagic strokes, increased vascular impedance, 
and progression of aortic valve insufficiency in HF patients chronically supported 
by CF LVAD [4, 29-31]. PF LVAD phasically unload the native ventricle, creating 
variable loading of the native myocardium while maintaining end-organ perfusion, 
which may affect weaning and promotion of myocardial recovery [32]. CF LVAD 
continuously unload the native ventricle providing consistent ventricular loading. 
However, this makes it difficult to modulate the myocardial load without altering 





Gradual reloading of the heart while maintaining end-organ perfusion could be 
achieved by modulation of blood pump motor speeds/flow. Modulation of blood 
pump motor speeds/flow has been suggested as a potential mechanism to 
artificially increase vascular pulsatility in both ventricular assist devices [33-39] 
and total artificial hearts[40-43]. Flow modulation of ventricular assist devices is 
affected by the timing of flow modulation to the native myocardial contraction. 
Early LVAD modulation strategies focused on asynchronous modulation of LVAD 
flow, as it was simpler to implement [33, 38].  Cox et al., Letsou et al., and Shi et 
al. simulated sinusoidal synchronous LVAD flow modulation but did not vary the 
timing of LVAD flow modulation [35, 36, 39]. Vandenberghe et al. varied the 
timing of synchronous support but did not vary the LVAD flow modulation 
amplitude or pulse width. Further, Vandenberghe et al. derived model 
parameters from sheep which is different from human values [34] . The effects of 
synchronizing and timing of the modulation of LVAD motor speeds/flow to the 
native myocardium, modulation amplitude, and modulation width have only 
recently been reported as a byproduct of this thesis work [44].  
 
In this study, the effects of timing and synchronizing the LVAD motor speed and 
flow modulation, modulation amplitude, and modulation widths on the native 
ventricle and vasculature are investigated. Experiments were performed using a 














Computer simulation is an important step in the design process for LVAD control 
strategies and has been repeatedly shown valuable in the literature. Testing in 
computer simulation is a financially efficient and time saving way to test multiple 
iterations of various control designs.  Several strategies of LVAD control have 
been studied using computer simulation models including suction detection[45-
47], estimation and control of aortic pressure[48], exercise responsive control[49], 
and preload dependent pump flow[50]. We hypothesized that modulation of 
LVAD flow will increase arterial pressure pulsatility and alter left ventricular 
pressures, volumes, and workloads. Further, the effect on the native ventricle will 
be dependent on timing, amplitude, and pulse width of the LVAD flow modulation. 
The objective of this computer simulation study was to investigate the effects of 
timing and synchronizing LVAD flow modulation on the native ventricle and 





Methods and Materials 
 
Cardiovascular System Simulation  
 
A previously reported computer simulation model of the human cardiovascular 
system was modified to simulate heart failure using Matlab (Mathworks, MA). 
This computer simulation model was validated and has been used in previous 
studies to develop and test physiologic control strategies for mechanical 
circulatory support devices [4, 51-53]. A more detailed description of the 
simulation model is provided by Giridharan et. al[53].  
 
Briefly, the computer model subdivides the human circulatory system into an 
arbitrary number of lumped parameter blocks, each characterized by its own 
resistance, compliance, pressure, and volume of blood. Two idealized elements, 
resistance and storage, were used to characterize each block. The storage 
element provides zero resistance to flow, whereas the resistive element has zero 
volume. The model has 13 elements: four valves and nine blocks, including left 
and right ventricles, pulmonary and systemic circulations, vena cava, aorta, and 




compliance. The remaining blocks were characterized by passive elements. The 
coronary block consisted of time varying resistive and compliance elements.  
 





A model of a CF LVAD was integrated into previously published computer 
simulation model. Simulations were conducted to predict acute hemodynamic 
responses including coronary flows, ventricular pressure-volume loops, left 
ventricular external work, arterial pressures, and vascular pulsatility parameters 
(mean arterial pressure (MAP), energy equivalent pressure (EEP), surplus 
hemodynamic energy (SHE)) for partial (mean LVAD flow = 2.5 ± 0.1 L/min) and 





The LVAD flow modulation waveforms were constructed using a piecewise-
defined function with no LVAD retrograde flows. CF LVAD retrograde flows 
increase vascular pulsatility, but was not considered as they can increase 
hemolysis and lead to higher myocardial loads and ventricular wall stresses. The 
piecewise-defined function was divided into pulse and nadir phases (Figure 4a). 
The pulse width was defined as the portion of the LVAD flow waveform where the 
instantaneous flow equaled or exceeded the mean flow. The nadir phase was 
defined as the portion of the LVAD flow waveform where the instantaneous flow 
was less than or equaled the mean flow. Unification of the pulse and nadir 
phases created one complete LVAD flow waveform. Pulse widths from 20%-80% 
were simulated for each level of synchronous LVAD flow modulation. Pulse 
widths of 40%, 50% and 60% were created with the same flow modulation 
amplitudes and mean flows (Figure 4b). The pulse width conditions of 20%, 30%, 
70%, and 80% required varying flow modulation amplitudes but maintained same 
average flow rates. Both asynchronous LVAD flow modulation (20 beats/min, 40 
beats/min, 60 beats/min) and synchronous LVAD flow modulation (80 beats/min) 





Figure 4: (a) LVAD flow waveform with a 40% pulse width. (b) LVAD flow 
waveforms with 40%, 50%, and 60% pulse width. (c) LVAD flow waveforms 
with high, medium, and low flow modulation. (d) A 40% pulse width LVAD 
flow waveform with a 40% and 60% time shift. 
 
Different levels of LVAD flow modulation amplitudes were simulated for partial 
and full LVAD support testing. Partial support LVAD flow modulations were 
tested at low pulsatility, medium pulsatility, and high pulsatility. The amplitudes of 




medium, and high pulsatility modes, respectively. The amplitudes of full support 
LVAD flow modulations were 1 L/min, 4.5 L/min, and 9 L/min for low, medium, 
and high pulsatility modes, respectively (Figure 4c). The effects of timing the 
synchronous LVAD flow modulation to the native myocardial contraction were 
tested by varying the time shift, which represents the timing of the LVAD flow 
modulation in relation to the cardiac cycle (Figure 4d).  Specifically, LVAD flow 
modulation was initiated at 0% (co-pulsation mode - both native ventricular 
contraction and LVAD flow modulation are in unison), 20%, 40% (counter 
pulsation mode-LVAD flow modulation initiated during native ventricular diastole), 
60%, and 80% of the native cardiac cycle, A total over 150 combinations of 
varying pulse widths, beat frequencies, time shifts, and amplitudes of CF LVAD 
flow were simulated. 
 
All simulations were initiated with limit cycle (steady state) values of a failing 
heart. At time t=0, the simulated device was turned on with a flow modulation. 
The model circulatory system reached a limit cycle within 300 cardiac cycles. The 
simulation was continued to 500 cardiac cycles. The mean values of pressures, 
flows, and volumes were reported only for the last 50 beats. The computer model 









Effect of level of support 
 
 
Increasing levels of CF LVAD support, irrespective of CF LVAD flow modulation, 
reduced LVEW, pulse pressures, MAP and SHE and augmented diastolic 
coronary flow and myocardial supply demand ratio (CoF/LVEW), from baseline 
heart failure values (no LVAD support) (Tables 1-3). CF LVAD flow modulation 
increased the range of LVEW, pulse pressures, coronary flows, MAP, SHE and 
myocardial supply demand ratios achievable with the same mean CF LVAD flow 
















Flow               
(L/min) 
LVEW                   
(mmHg*mL) 




      
Failure 35 0 2854 59 2 
Partial Support 15 2.5+0.1 1792 64 3 
Full Support 1 5.0+0.1 411 80 14 
 
Table 1: Pulse pressure, left ventricular external work (LVEW), diastolic 
coronary flow (dCoF), and myocardial supply demand ratio (CoF/LVEW) 
obtained during baseline heart failure and with partial and full CF LVAD 
support without any CF LVAD flow modulation. 
 
 
Parameter Pulse Pressure     (mmHg) 
LVEW                   
(mmHg*mL) 











Full Support 1 - 21 76 - 830 73 - 85 7 - 75 
Partial Support 14 - 21 1417 - 2220 61 - 68 2 - 3 








Full Support 2 - 52 317 - 500 77 - 82 11 - 18 
Partial Support 18 - 26 1562 - 1873 63 - 66 2 - 3 
 
Table 2: Range of pulse pressures, left ventricular external work (LVEW), 
diastolic coronary flow (dCoF), and myocardial supply demand ratio 
(CoF/LVEW) obtained by modulating the CF LVAD flow. These results 
demonstrate that modulation and timing of CF LVAD flow resulted in a 
range of LVEW and CoF without altering the mean LVAD flow, which may 
enable LVAD weaning protocols and myocardial recovery strategies 






Effect of flow modulation amplitude: 
 
 
Greater LVAD flow modulation amplitudes increased arterial pressure pulsatility 
and Surplus Hemodynamic Energy (SHE). Synchronous full support LVAD with 
the high flow modulation of 9 L/min (max/min = 10/1 L/min) produced arterial 
pulse pressures up to 19 mmHg while low flow modulation produced an arterial 
pulse pressure of 1.3 mmHg. For asynchronous full support, a maximum arterial 
pulse pressure of 52 mmHg was obtained with an LVAD flow modulation of 
9L/min (max/min = 10/1 L/min) at 20 bpm. Both are significantly greater than 
pulse pressure of 0.7 mmHg when providing full support with CF LVAD with no 
flow modulation. 
 
Increasing LVAD flow modulation augmented the range of LVEW, diastolic CoF, 
and the myocardial supply and demand ratio achievable for both full and partial 
support (Figure 5). At full LVAD support test condition, LVEW range increased 
from 294 – 485 mmHg*mL at low LVAD flow modulation test conditions to 76 – 
830 mmHg*mL at high LVAD flow modulation test conditions. During full LVAD 
support, the range of diastolic CoF and myocardial supply and demand ratio 
increased from 77 - 81 mL/min and 12 - 17(mmHg*mL*10-2)-1 at low LVAD flow 
modulation test conditions to 73 - 85 mL/min and 7 - 75 (mmHg*mL*10-2)-1 at high 




of flow modulation resulted in a MAP range of 95 - 98 mmHg, EEP range of 96 - 
106 mmHg, and SHE range of 697 – 10863 ergs/cm3.  
 
Figure 5: The effect of amplitude modulation and timing on (a)Surplus 
hemodynamic energy (SHE), (b) left ventricular external work (LVEW) and 
(c) myocardial supply and demand ratio (CoF/LVEW. Effects of timing are 
amplified with increased modulation amplitude. Effects are shown for a 
synchronous 60 percent pulse width at low (1L/min), medium (4.5 L/min), 
and high (9 L/min) LVAD flow amplitude modulations. These results 
indicate that higher amplitude modulation leads to higher SHE, and a larger 
variation in LVEW and myocardial supply demand ratio (CoF/LVEW) based 





During partial LVAD support, LVEW range increased from 1675 - 1888 
mmHg*mL at low LVAD flow modulation test conditions to 1417 - 2220 
mmHg*mL at high LVAD flow modulation test conditions. The range of diastolic 
CoF and myocardial supply and demand ratio increased from 63 - 65 mL/min and 
2.5 - 2.8 (mmHg*mL*10-2)-1   at low LVAD flow modulation test conditions to 61 - 
68 mL/min and 2.1 - 3.4 (mmHg*mL*10-2)-1 at high LVAD flow modulation test 
conditions. During partial LVAD support conditions, different levels of flow 
modulation resulted in MAP, EEP, and SHE ranges from 78 - 81 mmHg, 80 - 82 
mmHg, and 333 - 2144, respectively.  
 
 
Effect of Timing: 
 
Timing during synchronous LVAD modulation affected LVEW, diastolic CoF, and 
CoF/LVEW significantly (Figures 5,6,7). Asynchronous LVAD modulation timing 
had negligible effect on any measured parameter, when averaged over several 
cardiac cycles (Figure 5). During synchronous full LVAD support with high 
pulsatile waveforms, the maximum achievable LVEW, occurred at time shift of 
0% and ranged from 407 – 662 mmHg*mL. Minimum achievable LVEW occurred 
at time shifts of 40% to 60%, ranged from 76-149 mmHg*mL. Maximum diastolic 
CoF (up to 85 mL/min) occurred when the apex of the LVAD flow modulation 




Minimum diastolic CoF occurred when the apex of the LVAD flow modulation 
waveform coincided with native ventricular systole (co-pulsation). A change in 
time shift from 0% to 40% corresponded with a change in CoF/LVEW ranges of 7 






Figure 6: The effects of pulse width and timing on (a) Surplus 
hemodynamic energy (SHE), (b) left ventricular external work (LVEW) and 
(c) myocardial supply and demand ratio (CoF/LVEW). Counterpulsation 
(60% pulse width and 40% time shift) produced minimum LVEW and 
maximum CoF/LVEW. Effects are shown for synchronous  high (9 L/min) 
LVAD flow amplitude modulations at each pulse width (40%, 50%, 60%). 
These results indicate that 60% pulse width in co-pulsation mode (0 time 
shift) produces the highest pulsatility (SHE) while counter pulsation  mode 







Figure 7: The effects of LVAD flow modulation rate and timing on (a) 
Surplus hemodynamic energy (SHE), (b) left ventricular external work 
(LVEW) and (c) myocardial supply and demand ratio (CoF/LVEW). Slower 
LVAD flow modulations produced higher SHE. Timing showed little effect 
on SHE, LVEW, and CoF/LVEW for asynchronous LVAD flow modulation 
(20 BPM. 40 BPM. 60 BPM) as opposed to the effects seen on synchronous 





The effects of timing the LVAD flow modulation during partial support test 
conditions were similar to full support test conditions. During partial LVAD 
support, maximum LVEW ranged from 2057 - 2220 mmHg*mL at 0% time shift. 
Minimum LVEW (1417 – 1510 mmHg*mL) were obtained during time shifts of 40-
60%. Maximum diastolic CoF (67 - 68 mL/min) occurred when the maximum 
LVAD flow was during ventricular diastole, while minimum diastolic CoF (61-– 62 
mL/min) occurred when maximum LVAD flow was during ventricular systole. 
CoF/LVEW ranged from 2.1 - 2.3 (mmHg*mL*10-2)-1   at 0% time shifts to 3.2 - 
3.4 (mmHg*mL*10-2)-1 at 40% time shifts.  
 
 
Effect of pulse width 
 
 
Changing the CF LVAD flow modulation pulse width without altering pulse 
amplitude affected LVEW, diastolic CoF, and CoF/LVEW (Figure 6). However, 
the changes are not as pronounced as the effects of timing.  
 
At full LVAD support test condition with synchronous modulation, the ranges of 
LVEW were 149 - 830, 139 - 739, and 76 - 706 mmHg*mL for pulse widths of 
40%, 50%, and 60%. Diastolic CoF changed from 73 - 83, 76 - 84, 75 - 85 
mL/min at 40%, 50%, and 60% pulse widths. CoF/LVEW at 40%, 50%, and 60% 




(mmHg*mL*10-2)-1.  Pulse widths of 20%, 30%, 70%, and 80% required alteration 
of the CF LVAD flow modulation amplitude to maintain the average flow rates. 
Thus, the effect of timing could not be independently discerned from the effect of 
altered CF LVAD flow modulation amplitude for these pulse widths. During 
asynchronous modulation at full LVAD support, the ranges of LVEW were 351 - 
500, 355 - 459, and 317 - 420 mmHg*mL for pulse widths of 40%, 50%, and 60%. 
Pressure-volume loops are shown in Figure 8. 
 
Figure 8: Pressure volume loops for no LVAD support, CF LVAD support, 
pure co-pulsation LVAP flow modulation (0% time shift, 40% pulse width), 
pure counter pulsation LVAD flow modulation (40% time shift, 60% pulse 
width, LVAD flow modulation with a 50% pulse width starting at systole 
(50%PW co-pulsation), and LVAD flow modulation with a 50% pulse with 
starting at diastole (50%PW counter-pulsation). Ventricular volumes were 





Diastolic CoF changed from 77 - 80, 78 - 81, and 78 - 82 at 40%, 50%, and 60% 
pulse widths. CoF/LVEW at 40%, 50%, and 60% pulse widths corresponded to 
ranges of 11 - 16, 13-– 16, and 14 - 18 (mmHg*mL*10-2)-1.  
 
During partial LVAD support with synchronous LVAD flow modulation, LVEW 
ranged from 1493 - 2045, 1491-  2117, 1458- 2034, and 1555 - 1944 mmHg*mL 
at 20%, 40%, 60%, and 80% pulse widths respectively. The same pulse widths 
corresponded with diastolic CoF ranges of 62 - 67, 62 - 67, 62 - 68, and 63 - 66 
mL/min, respectively. At 20%, 40%, 60%, and 80% pulse widths, the range of 
myocardial supply and demand ratios varied from 2.3 - 3.2, 2.2 - 3.2, 2.3 - 3.3, 
and 2.4 - 3.0 (mmHg*mL*10-2)-1. 
 
Asynchronous modulation at partial LVAD support produced LVEW ranges of 
1562 - 1873, 1641 - 1856, and 1637 - 1770 mmHg*mL at pulse widths of 40%, 
50%, and 60%. Diastolic CoF was 63 - 66 mL/min for all pulse widths.  The same 
pulse widths corresponded to CoF/LVEW ranges of 2.5 - 3.0, 2.5 - 2.8, and 2.6 - 
2.9 (mmHg*mL*10-2)-1. CF LVAD flow modulation pulse width does not 







Synchronous vs. Asynchronous Modulation 
 
 
During asynchronous LVAD flow modulation, LVEW, diastolic CoF, LVV and 
CoF/LVEW varied between cardiac cycles in one LVAD flow modulation 
waveform period (Figures 9,10,11) while consistent ranges obtained during 
synchronous LVAD support and continuous flow LVAD support. Decreasing the 
rate of asynchronous full support LVAD flow modulation increased the achievable 
arterial pressure pulsatility, EEP, and SHE. A maximum arterial pulse pressure of 
59 mmHg was achieved at a slow LVAD flow modulation rate of 20 bpm (Figure 
9). This is significantly greater than synchronous full support CF LVAD with high 
flow modulation (19 mmHg at a modulation frequency of 80 bpm). However, 
synchronous full and partial support LVAD flow modulations allowed for a larger 
range of average LVEW, diastolic CoF, and myocardial supply and demand ratio 






Figure 9: AoP, LVP, LVV for Normal CF LVAD, Synchronous CF LVAD with 
high flow modulation, and asynchronous CF LVAD with high flow 
modulation. Synchronous CF LVAD modulation increases AoP Pulsatility 
while maintaining consistent ranges of LVP and LVV. Asynchronous CF 
LVAD modulation at 20 BPM increases pulse pressure over synchronous 





Figure 10: Values of MAP, EEP and SHE for Asynchronous, Synchronous, 
Normal (no CF LVAD flow modulation), and no CF LVAD support. These 
results demonstrate that CF LVAD flow modulation does not affect the 
mean arterial pressure. However, asynchronous CF LVAD flow modulation 






Figure 11: Maximum and minimum values of left ventricular volume (LVV) 
and aortic pressure (AoP), pulse pressure, mean arterial pressure (MAP), 
and ventricular pressure-volume loops showing the varying ventricular 
pressures and volumes for different modulation rates of CF LVAD. 
Specifically, higher left ventricular volume variability occurs at lower CF 







CF LVAD bpm MAP   (mmHg) EEP  (mmHg) SHE (erg/cm3) 






t 20 bpm 95.9 - 98.1 103.6 - 106.1 9,976 - 10,863 
40 bpm 95.9 - 98.0 98.5 - 100.8 3,325 - 3,752 
60 bpm 96.0 - 97.9 97.2 - 99.3 1,567 -1,850 
80 bpm 95.6 - 98.0 96.3 - 98.9 697 - 1,301 







rt 20 bpm 79.9 - 80.2 81.3 - 81.6 1,583 - 2.058 
40 bpm 79.6 - 80.4 80.5 - 82.0 1,097 - 2,144 
60 bpm 79.9 - 80.2 80.8 - 81 1,047 - 1,399 
80 bpm 78.6 - 81.3 80.0 - 82.1 333 - 1,899 
 
Table 3: Range of values of mean arterial pressure (MAP), energy 
equivalent pressure (EEP), and surplus hemodynamic energy (SHE) 
obtained with high modulated CF LVAD flow during full and partial support 





The results of this computer simulation study establish that arterial pulsatility and 
ventricular work can be affected significantly by modulating CF LVAD flow. 
Arterial and ventricular hemodynamic waveforms were altered by varying the 
timing, amplitude, and width of the CF LVAD flow modulation pulse for the same 




be obtained for the same mean CF LVAD flow rate by altering the CF LVAD flow 
modulation. Currently, to increase LVEW to wean the patient from the device or 
to promote myocardial recovery, the CF LVAD flow rate is lowered, which may 
affect end-organ perfusion. Modulation and timing of CF LVAD flow resulted in a 
range of LVEW and CoF without altering the mean LVAD flow. Thus, modulation 
of CF LVAD flow may be beneficial in developing control strategies for CF LVAD 
to obtain a desired myocardial oxygen supply and work level, particularly towards 
optimizing the myocardial recovery process and developing weaning protocols 
for patients who are likely to experience myocardial recovery without changing 
the average CF LVAD flow and affecting end organ perfusion. 
 
Diminished pressure pulsatility due to CF LVAD support has been reported to 
diminish aortic wall thickness, and volume ratio of smooth muscle cells [4, 54].  
Further, anecdotal reports have indicated the frequent development of adverse 
events including gastrointestinal bleeding, hemorrhagic strokes, increased 
vascular impedance and progression of aortic valve insufficiency in HF patients 
chronically supported by CF LVAD[4, 29-31]. The increase in vascular pulsatility 
due to CF LVAD flow modulation may prevent or help reduce the severity of 





Maximum LVEW occurred at 0% time shift (co-pulsation mode) while minimum 
LVEW occurred at 40% time shift (counter-pulsation mode). Counterpulsation 
mode produced higher myocardial supply demand ratio (CoF/LVEW) but reduced 
vascular pulsatility compared to the co-pulsation mode. However, vascular 
pulsatility with counter pulsation  mode was still higher than what was observed 
with no CF LVAD flow modulation. Altering the timing affected the SHE and EEP 
values but the highest values of SHE were obtained during asynchronous 
support with the LVAD modulating at 20 bpm (Figure 7, Table 3). During 
synchronous LVAD flow modulation, co-pulsation mode (0% time shift) resulted 
in higher SHE values compared to the counter pulsation mode (40% time shift). 
These results suggest that some optimization may be needed to tailor the CF 
LVAD flow modulation strategies to individual patients. During asynchronous 
LVAD flow modulation at low frequencies and high flow modulations, maximum 
pressure pulsatility was achieved. However, High LVAD flow over the period of 
several cardiac cycles creates favorable conditions for suction events. Algorithms 
to detect and prevent suction have been developed are currently used in 
LVADs[55, 56]. 
 
A normal human heart produces a peak flow rate of 30-35 L/min and minimum 
flow of ~0 L/min, resulting in an aortic pressure pulsatility of approximately 40 




an aortic pressure pulsatility of 30-35 mmHg due to higher vascular impedance 
[4]. We limited the peak flow rate of the simulated CF LVAD flow waveform to 10 
L/min to keep within the performance limitations of current LVADs. The minimum 
flow rate was limited to 1 L/min to prevent retrograde flow. These limitations in 
simulated peak and minimum CF LVAD flows limited the maximum achievable 
arterial pressure pulse with synchronous CF LVAD support to 19 mmHg. The 
achievable arterial pressure pulse can be significantly increased by allowing 
higher values of peak CF LVAD flow rates with improvement in LVAD technology.  
While retrograde flows also increase aortic pressure pulsatility, it should be 





There are several limitations associated with the computer simulation model. The 
performance of the computer simulation during failing heart test condition is 
representative of clinical observations from a purely hemodynamic viewpoint. 
Clearly, a computer simulation is not intended to replace the importance and 
significance of in vivo models and is incapable of replicating all expected clinical 
responses, but it does provide a valuable initial step. For instance, the simulation 




regulatory proteins, or changes in genetic phenotype, but it can demonstrate 
feasibility of concepts. However, these limitations have been addressed in the in-
vivo animal model studies detailed in chapter 4.  Computer models rely upon 
many assumptions that may have a dramatic influence upon the interpretation of 
results. For example, the computer model for this study assumes ideal valves 
that open and close instantaneously, Newtonian blood, a constant diastolic 
ventricular compliance, does not account for inertial or gravitational effects, and 
the effects of wave reflection. The effect of LVAD flow modulation in mock 
circulation and animal experiments, presented in chapters 3 and 4, overcome 
some of these limitations. Importantly, blood behaves as a Newtonian fluid at 
higher velocities in large vessels and the LVAD. The computer simulation does 
enable prediction of hemodynamic and ventricular pressure-volume responses. 
The effect of CF LVAD flow modulation can also be quantified in in-vitro mock 
circulation systems and in-vivo animal models. However, these models have 
several significant limitations not present in the computer simulation that may 
affect the accurate quantification of aortic pulse pressure and LVEW. Specifically, 
mock circulation models usually lump total systemic compliance which is 
significantly lower than aortic compliance[58]. The lower value of lumped 
systemic compliance would artificially augment pressure pulsatility, which may 
lead to reports of up to 61 mmHg of pressure pulsatility with less than 5 L/min of 




arterial compliance values than humans [59]. These altered compliance values 
would lead to an inaccurate estimation of aortic pressure pulsatility, Figures 9, 
20, and 27. Further, in-vitro mock circulation systems typically underestimate the 
reduction in left ventricular peak pressures due to pneumatic/hydraulic drivers, 
which may lead to inaccurate estimation of LVEW. Despite its limitations, a 
computer simulation model with a simulated aorta may be the simplest method to 
adequately quantify the effects of CF LVAD flow modulation. Modulation of CF 
LVAD rpm/flow would increase power consumption and bearing wear which may 
be minimized in next generation magnetically suspended CF LVAD. To ensure 
that the strategies presented in this manuscript are pump independent, we use 
flow modulation instead of rpm/power modulation. Pump inertia, friction, and 
loading profiles will vary from pump to pump and affect the relationship between 
rpm/power modulation and flow modulation. The rpm/power modulation needed 
to achieve the flow modulation will be different for each device in mock circulation 
and animal studies only being representative of the specific pumps used in each 
study.  The values of SHE, EEP, pressures, flows, and work are representative 
and clinically relevant values obtained from literature but may vary due to intra-
patient variability. Despite these limitations, it is hoped that the computer 
simulation findings enable the further development and testing of new control 





















While they cannot replace in-vivo animal testing and clinical trials, in-vitro mock 
loop testing is an important step in the design process. In-vitro mock loops are 
used for experimental protocol development, device performance testing, 
feedback control algorithm design, as well as training of clinical staff. The in-vitro 
test system has the ability to mimic the Frank-Starling response and produces 
physiologic characteristic hemodynamic measurements and pressure volume-
relationships. The in-vitro mock loop used in this testing has been verified and 
well published with multiple devices having been evaluated using it [58, 60-63]. 
Cases found to yield the most promising results (i.e. co-pulsation and counter-
pulsation) were further tested using this experimental setup. We hypothesized 
that modulation of LVAD RPM will increase arterial pressure pulsatility and 
enable alteration of left ventricular pressures, volumes, and workloads. Further, 




be dependent on LVAD modulation timing. The objective of this mock circulation 
study was to investigate the effects of LVAD RPM modulation on the ventricle 
and vasculature with varying modulation amplitudes, widths, and frequencies and 
compare the results to computer simulation. 
 
Methods and Materials 
 
Mock Circulatory Loop  
 
The mock circulation system used in this experiment consisted of a silicone left 
ventricle, aorta, arterial resistance and compliance, venous reservoir and atrial 
compliance (Figure 12). Ventricular pressure, heart rate, loop volume, 
resistances, and compliances were adjusted to reproduce hemodynamic 
pressure and flow waveforms of the physiology of an adult human in heart failure 
based on clinical findings. Aortic (proximal and distal) and LVAD flows were 
measured using Transonic Flow Probes (Transonic Systems, Ithica, NY). Aortic 
(proximal and distal), and atrial pressures were measured using single tipped 
Millar pressure catheters and left ventricle pressure and volume were measured 
using Millar a pressure-volume conductance catheter (Millar Instruments, TX). 
Ventricle systolic and diastolic time periods and pressure, vacuum, and motor 




Germany). A HeartWare (Miami Lakes, FL) HVAD was used as the LVAD in this 
study. The centrifugal pump has been implanted regularly in Europe, is currently 
awaiting FDA approval for bridge to transplantation, and is undergoing clinical 
trials for destination therapy in the US [64, 65]. 
 
Figure 12: Mock Circulation loop with (a) left ventricle, (b) HeartWare LVAD, 





The LVAD controller was programmed by engineers at HeartWare under the 




13). In the mock circulation studies, the controller modulated the LVAD speed up 
and down by the same given RPM step around a user defined base speed. The 
HVAD has pump has operational speed limits of 1800 – 4000 RPM. Delta T was 
defined as the period of time the pump was in high or low RPM (pulse and nadir 
rpm). The pump would be in the high RPM for Delta T and the low RPM for Delta 
T resulting in one modulation period being twice the value of Delta T. For 
example, if a Delta T of 0.4 sec was chosen at a 2900±1100 RPM (mean 
RPM±modulation amplitude) modulation, the pump would operate at 4000 RPM 
for 0.4 seconds followed by 1800 RPM for 0.4 seconds and then repeat the cycle. 
The complete modulation cycle would take 0.8 seconds.   
 









Three ventricle contractilities (high, medium, and low) were used in this study. 
High contractility produced baseline heart failure pressures in the mock loop with 
no LVAD. High, medium, and low contractility resulted in peak ventricle 
pressures of 142 mmHg, 104 mmHg, and 80 mmHg. The mock circulation cannot 
automatically reduce the contractility based on myocardial load. Thus, different 
ventricular contractilities were simulated to match a range of ventricular 
contractilities that is observed during unloading/ of the native ventricle 
using VAD/LVAD support. The cardiac cycle produced by the driver was 0.795 
sec (75.5 BPM), while the LVAD operated at .800 seconds.  
 
Base speeds for this study were chosen at 2900 and 3200 RPM. A base speed 
of 2900 allowed for maximum RPM modulation (2900±1100 RPM) (base RPM ± 
modulation RPM) and steps of 2900±800 RPM, 2900±500 RPM, and 2900±300 
RPM. 3200 RPM completely unloaded the ventricle and was chosen as a full 
support baseline with no modulation. Modulations were done around a 3200 
RPM base speed at 3200±800 RPM, 3200±500 RPM, and 3200±300 RPM. In 




periods of 0.8 seconds, 1.0 seconds, 1.6 seconds, and 3.2 seconds. For 
synchronous modulation, the LVAD RPM modulation period was set at 0.4 
seconds. The 0.005 second offset between LVAD cycle period (0.8 seconds) and 
cardiac cycle (0.795 seconds) allowed for the LVAD to pass from co-pulsation to 
counter pulsation LVAD RPM modulation. The small 5 ms difference between the 
native ventricle and the pump produced a slightly asynchronous support that 
would capture the effect of timing of the LVAD to the native ventricle in a 200 
second data set. At each of the three contractilities, the LVAD was modulated at 
the described RPM levels at each of the modulation periods. Additionally data 
sets were recorded for the LVAD running in CF fashion at each contractility in 
100 RPM steps (i.e. 2000 RPM, 2100 RPM, 2200 RPM, etc.  
 
 
Data Analysis  
 
Data was analyzed using Matlab (MathWorks, Natick, MA) and Hemodynamic 
Evaluation and Assessment Research Tool (HEART) program [66]. Pressure, 
flow, and volume waveforms were used to calculate the following hemodynamic 
parameters: cardiac output; aortic systolic, diastolic, and mean pressures; left 
ventricular systolic, end diastolic, and peak pressures; left ventricular external 




no LVAD RPM modulation, all hemodynamic parameters were calculated on a 
beat-to-beat basis. Three beats were averaged for calculating co-pulsation and 
counter pulsation hemodynamics; the beat found to be in pure co-pulsation or 
counter pulsation and the previous and following beats. When evaluating 
synchronous modulation, the hemodynamic values obtained for the modulation 
beats were compared to those when operating the LVAD in a CF fashion at flow 
within 10% of mean LVAD flow. Asynchronous modulation cases were evaluated 
over the full LVAD modulation cycle (i.e. multiple beats) and reported values are 
the average of 200 seconds of RPM modulation. Pressure-volume loops were 
constructed by plotting ventricular pressure against ventricular volume, where 
each loop represents one complete cardiac cycle (one beat). Characterizing 
hemodynamic parameters and pressure-volume loops were calculated for all 






Effects of Contractility 
 
Increased contractility led to greater flow through aortic valve during CF LVAD 




outflow graft, modulation of LVAD flow rates due to ventricle contraction, and 
LVAD speed necessary to achieve mean LVAD flows of 3.0±0.2L/min, 
4.0±0.2L/min, and 5.0±0.2L/min at high, medium, and low ventricle contractilities.  
Decreasing ventricle contractility resulted in lower LVAD speed necessary for 
equivalent LVAD flow. Additionally, increased ventricle contractility resulted in a 
higher change in LVAD flow. At LVAD flow rates of 3.0±0.2L/min, 4.0±0.2L/min, 
and 5.0±0.2L/min, the change in LVAD flow was 2.6L/min, 2.5L/min, and 
2.3L/min for low contractility, 3.6L/min, 3.4L/min, and 3.2L/min for medium 
contractility, and 5.4L/min, 4.8L/min, and 4.4L/min for high contractility.  Further, 
lower ventricle contractility resulted in reduced flow through the aortic valve. At 
an LVAD flow rate of 3.0±0.2L/min, flow through the aortic valve diminished from 
1.7L/min at high contractility to 0.8L/min at medium contractility and 0.4L/min at 







Table 4: Flow through the aortic valve proximal to the LVAD outflow graft 
(AoFroot), maximum and minimum LVAD flow rates (max/min VADF), and 
LVAD speed (RPM) necessary to achieve LVAD flows (VADF) of 
3.0±0.2L/min, 4.0±0.2L/min, and 5.0±0.2L/min at high, medium, and low 
ventricle contractilities.  The LVAD was operating in a CF fashion and the 
variation in flow shown in max/min VADF is due to contraction and 
relaxation of the ventricle.  
 
 
During synchronous co-pulsation LVAD RPM modulation, increased ventricular 
contractility increased maximum and minimum LVAD flows (Table 5). Change in 
LVAD flow increased from 9L/min at low contractility to 9.7L/min and 11.1L/min at 
medium and high ventricular contractilities, respectively. In co-pulsation LVAD 
RPM modulation, mean LVAD flow increased as ventricle contractility decreased 
for maximum LVAD speed modulation (2900±1100 RPM). Differing from co-
pulsation LVAD RPM modulation, in counter pulsation mode, LVAD flow did not 
vary greatly between high, medium, and low contractilities with flow rates of 
4.1L/min, 4.3L/min, and 4.1 L/min, respectively. Similarly to continuous flow, 
decreased contractility resulted in a reduction in flow through the aortic valve for 
AoFroot max/min 
VADF
RPM AoFroot max/min 
VADF
RPM AoFroot max/min 
VADF
RPM
3.0±0.2 1.7 5.9/0.5 2800 0.8 4.9/1.3 2400 0.4 4.3/1.7 2200
4.0±0.2 1.0 6.5/1.7 3100 0.2 5.9/2.5 3000 0.0 5.3/2.8 2900
5.0±0.2 0.2 7.3/2.9 3500 0.0 6.6/3.4 3400 0.0 6.1/3.8 3500
VADF 





both co-pulsation and counter pulsation LVAD RPM modulation. During co-
pulsation LVAD RPM modulation flow through the aortic valve was 1.5L/min, 
0.3L/min and 0.0L/min and during counter pulsation LVAD RPM modulation flow 
through the aortic valve was 1Lmin, 0.1L/min, and 0.0L/min for high, medium, 
and low ventricle contractility, respectively. Low ventricular contractility best 
mimics the effects of LVAD unloading the native ventricle and is used in the 




Table 5: Flow through the aortic valve proximal to the LVAD outflow graft 
(AoFroot), mean LVAD flow (VADF), and maximum and minimum LVAD 
flow rates (max/min VADF) at high, medium, and low ventricle 
contractilities for co-pulsation and counter pulsation  LVAD flow 
modulation.   
 
Synchronous vs. Asynchronous Modulation 
 
During asynchronous LVAD RPM modulation, LVEW, LVV, and mean LVAD flow 



















Co-pulsation 1.5 2.9 8.5/-2.6 0.3 3.5 8.4/-1.3 0.0 3.6 8.2/-0.8








as compared to consistent ranges obtained during synchronous LVAD support 
and continuous flow LVAD support. Decreasing the rate of asynchronous full 
support LVAD RPM modulation increased the achievable arterial pressure 
pulsatility, EEP, and SHE (Table 6).  
 
Table 6: Range of values of mean arterial pressure (MAP), energy 
equivalent pressure (EEP), and surplus hemodynamic energy (SHE) 
obtained with maximum modulated CF LVAD RPM around base RPMs of 
2900RPM and 3200RPM modulation periods of at 1.6 sec, 0.8 sec, 0.5 sec, 
and 0.4 sec (synchronous modulation). 
A maximum arterial pulse pressure of 65 mmHg was achieved at a slow LVAD 
RPM modulation rate of with a 1.6 second modulation period (3.2 second cycle 
period) of 2900±1100RPM. This is considerably greater than synchronous co-








Effects of Timing 
 
Co-pulsation and counter pulsation modulation of LVAD RPM (2900±1100RPM) 
both increased pulse pressure 210% and 98%, respectively, as compared to 
normal CF LVAD operation with similar mean LVAD flow. However, counter 
pulsation yielded more than a 50% smaller percent increase from normal CF 
LVAD operation in aortic pressure pulsatility as compared to the greater percent 





Figure 14: Percent change in pulse pressure during co-pulsation and 
counter pulsation LVAD RPM modulation from CF LVAD of similar mean 
flow (mean RPM ± modulation RPM). 
 
As compared to co-pulsation, counter pulsation LVAD RPM modulation resulted 
in higher mean LVAD flow (3.6L/min vs. 4.1L/min) and MAP (76 mmHg vs. 89 
mmHg) at LVAD RPM modulation of 2900±1100 RPM (Figure 15). Co-pulsation 
(2900±1100 RPM) increased stroke volume 12% as compared to CF LVAD at 
similar flow. Alternatively, counter pulsation (2900±1100 RPM) reduced stroke 
volume 20% as compared to CF LVAD at similar flow (Figure 16).  Figure 12 
shows pressure volume loops for co-pulsation and counter pulsation at 
2900±1100 RPM and the corresponding pressure volume loops for CF LVAD 
with similar mean LVAD flow, 2700 RPM and 3000 RPM, respectively. Both co-
pulsation and counter pulsation of LVAD RPM at 2900±1100 RPM decreased 





Figure 15: Aortic pressure, left ventricular pressure, LVAD flow, mean 
LVAD flow and pressure volume loops for (a) co-pulsation LVAD 
modulation at 2900±1100 RPM, (b) CF LVAD at 2700 RPM, (c) counter 
pulsation LVAD RPM modulation at 2900±1100 RPM, and (d) CF LVAD at 
3000  RPM. Co-pulsation at 2900±1100 RPM and CF LVAD at 2700 RPM had 
similar mean LVAD flows. Further, counter pulsation at 2900±1100 RPM and 









Figure 16: Percent change in stroke volume during co-pulsation and 
counter pulsation LVAD RPM modulation from CF LVAD of similar mean 
flow (mean RPM ± modulation RPM).  
 
 
Figure 17: Percent change in LVEW during co-pulsation and counter 
pulsation LVAD RPM modulation from CF LVAD of similar mean flow (mean 





Effects of Modulation Amplitude 
 
Decrease in RPM modulation amplitude does not considerably change mean 
VADF. However, during co-pulsation LVAD RPM modulation a decrease in 
modulation amplitude slightly increased mean LVAD flow. Mean LVAD flow 
increased from 3.64 L/min to 3.69 L/min, 3.76 L/min, and 3.82 L/min at RPM 
modulation amplitudes of 1100 RPM, 800 RPM, 500 RPM, and 300 RPM, 
respectively, during co-pulsation LVAD RPM modulation with a base of 2900 
RPM. Alternatively, a decrease in LVAD RPM modulation slightly increased 
mean LVAD flow during counter pulsation LVAD RPM modulation. Changes in 
RPM modulation amplitudes of 1100 RPM, 800 RPM, 500 RPM, and 300 RPM 
with a base of 2900 RPM resulted in mean LVAD flows of 4.10 L/min, 4.08 L/min, 
4.01 L/min, and 3.98 L/min, respectively, for counter pulsation LVAD RPM 





Figure 18: Mean LVAD flow for co-pulsation and counter pulsation LVAD 
RPM modulation for base RPMs of 2900 RPM and 3000 RPM and for RPM 
modulation amplitudes of 1100 RPM, 800 RPM, 500 RPM, and 300 RPM. 
 
Decrease in RPM modulation amplitude resulted in diminished pulse pressures.  
All co-pulsation LVAD RPM modulations resulted in an increase of pulse 
pressure as compared to CF LVAD with a similar mean LVAD flow. Similarly, 
counter pulsation LVAD RPM modulation resulted in increased pulse pressures 
of 98%, 42%, and 36% for LVAD RPM modulations of 2900±1100 RPM, 
2900±800 RPM, and 3200±800 RPM. However, counter pulsation LVAD RPM 
modulations of 2900±500 RPM, 2900±300 RPM, 3200±500RPM, and 3200±300 
RPM resulted in diminished pulse pressures from CF LVAD with a similar mean 
LVAD flow of -28%, -61%, -10%, and -56%, respectively (Figure 19). Slower 




change in pulse pressure trends resulted in similar trends for SHE. All co-
pulsations resulted in increased SHE from CF LVAD with a similar mean LVAD 
flow. Furthermore during counter pulsation LVAD RPM modulation, SHE 
decreased from CF LVAD with a similar mean LVAD flow of 92% and 92% at a 
base of 2900 RPM and 76% and 94% at a base of 3200 RPM, for RPM 
modulation amplitudes of 500 RPM and 300 RPM, respectively (Figure 21).  
 
 
Figure 19: Percent change in pulse pressure during co-pulsation and 
counter pulsation LVAD RPM modulation from CF LVAD of similar mean 
flow for base RPMs of 2900 and 3200 for RPM modulation amplitudes of 







Figure 20: Aortic pressure (AoP), left ventricular pressure (LVP), and LVAD 
flow (VADF) for (a) Normal CF LVAD, (b) Synchronous CF LVAD 
(2900±1100RPM) (mean RPM ± modulation RPM), and (c) asynchronous CF 
LVAD (2900±1100RPM). Synchronous CF LVAD modulation increases AoP 
Pulsatility while maintaining consistent ranges of left ventricular pressure 
and volumes. Slow asynchronous CF LVAD modulation at 19 BPM 
increases pulse pressure over synchronous modulation while creating 







Figure 21: Percent change in SHE during co-pulsation and counter 
pulsation LVAD RPM modulation from CF LVAD of similar mean flow for 
base RPMs of 2900 and 3200 for RPM modulation amplitudes of 1100 RPM, 
800 RPM, 500 RPM, and 300 RPM. 
 
During co-pulsation LVAD RPM modulation, change in LVAD flow was 
diminished as RPM modulation amplitude was decreased from 1100 RPM to 800 
RPM, 500 RPM, and 300 RPM. Specifically, for a base of 2900 RPM, change in 
LVAD flow decreased from 9.0 L/min at 1100 RPM to 7.2 L/min, 5.2 L/min and 
4.1 L/min at 800 RPM, 500 RPM, and 300 RPM, respectively. Similarly for base 
RPM of 3200, change in LVAD flow decreased from 7.1 L/min at 800 RPM 
modulations to 5.3 L/min at 500 RPM modulations and 4.1 L/min at 300 RPM 




LVAD with a similar mean LVAD flow of 242% (±1100 RPM), 176% (±800 RPM), 
112% (±500 RPM), and 60%(±300 RPM)  at base RPM of 2900 and 201%(±800 
RPM), 122%(±500 RPM), and 72%(±300 RPM)  at base RPM of 3200 (Figure 
22).  
 
During counter pulsation LVAD RPM modulation, change in LVAD flow was 
diminished as RPM modulation amplitude was decreased from 1100 RPM to 800 
RPM, 500 RPM, and 300 RPM. Specifically, for a base of 2900 RPM, change in 
LVAD flow decreased from 4.5 L/min (91%) at 1100 RPM to 3.0 L/min (29%), 1.6 
L/min (-36%) and 1.1 L/min (-56%)  at 800 RPM, 500 RPM, and 300 RPM, 
respectively. Similarly for base RPM of 3200, change in LVAD flow decreased 
from 3.3 L/min (42%) at 800 RPM modulations to 2.0 L/min (-14%) at 500 RPM 
modulations and 1.2 L/min (-49%) at 300 RPM modulations where the percent 
change from CF LVAD with a similar mean LVAD flow is in parentheses (Figures 







Figure 22: Change in LVAD flow for co-pulsation and counter pulsation 
LVAD RPM modulation for base RPMs of 2900 RPM and 3000 RPM and for 
RPM modulation amplitudes of 1100 RPM, 800 RPM, 500 RPM, and 300 RPM. 
 
 
Figure 23: Percent change in change in LVAD flow during co-pulsation and 
counter pulsation LVAD RPM modulation from CF LVAD of similar mean 
flow for base RPMs of 2900 and 3200 for RPM modulation amplitudes of 





The decrease in LVAD RPM amplitude modulation of 2900±1100 RPM, 800 RPM, 
and 500 RPM and 3200±800 RPM, 500 RPM, and 300 RPM during co-pulsation 
LVAD RPM modulation resulted in attenuation of change in stroke volume from 
CF LVAD of similar mean flow. Specifically, change in stroke volumes of 12%, 
11%, and 6% and 6%, 10%, and 8% resulted from co-pulsation LVAD RPM 
modulations of 2900±1100 RPM, 800 RPM, and 500 RPM and 3200±800 RPM, 
500 RPM, and 300 RPM. Counter pulsation LVAD RPM modulation resulted in 
change in stroke volumes of -20%, -18%, and -16% and     -14%, -11%, and -7% 
for the previously describe cases. Co-pulsation and counter pulsation LVAD RPM 
modulation of 2900±300 RPM resulted in increases of 36% and 35% respectively 








Figure 24: Percent change in stroke volume during co-pulsation and 
counter pulsation LVAD RPM modulation from CF LVAD of similar mean 
flow for base RPMs of 2900 and 3200 for RPM modulation amplitudes of 





The results of this study validate the conclusion that established arterial pulsatility 
and ventricular work can be affected significantly by modulating CF LVAD flow 
from previous work [44]. Arterial and ventricular hemodynamic waveforms were 
altered by varying the timing and amplitude of the CF LVAD RPM modulation and 





Diminished arterial pulse pressure has been suggested in a mechanism that 
results in increased bleeding events, acquired von Willebrande syndrome, and 
other adverse events prevalent in the clinical use of CF LVAD [67, 68]. Reduced 
pressure pulsatility that occurs during CF LVAD has been reported to diminish 
aortic wall thickness and volume ratio of smooth muscle cells [4, 54].  Additionally, 
anecdotal reports have indicated the frequent development of adverse events 
including gastrointestinal bleeding, hemorrhagic strokes, increased vascular 
impedance and progression of aortic valve insufficiency in HF patients chronically 
supported by CF LVAD [4, 29-31]. The increase in vascular pulsatility due to CF 
LVAD flow modulation may prevent or help reduce the severity of these adverse 
events associated with diminished pulsatility. Ando et al previously suggested 
that partial support co-pulsation LVAD RPM modulation can increase pulse 
pressure near levels of no support in healthy goats [69]. However, this was 
achieved with considerable retrograde flow through the device, which resulted in 
a 66% increase in end-diastolic LVP suggesting an increase in LVEW. 
Furthermore, at low RPM modulation amplitudes, counter pulsation LVAD RPM 
modulation would actually provide smaller pulse pressures than non-modulated 
CF LVAD flow. This further loss of pressure pulsatility may result in increased 





Both co-pulsation and counter pulsation LVAD RPM modulation resulted in a 
decreased LVEW as compared to CF LVAD. Further, counter pulsation LVAD 
RPM modulation caused a greater decrease in stroke volume than the same co-
pulsation LVAD RPM modulation and as a percent decrease from CF LVAD with 
similar mean LVAD flows. Alternately, counter pulsation LVAD RPM modulation 
reduced arterial pulse pressure as compared to co-pulsation LVAD RPM 
modulation. Counterpulsing by modulating LVAD RPM resulted in smaller 
variation in flow as the native ventricular contraction caused a high flow during 
systole while high LVAD RPM increased flow during diastole, leading to a smaller 
variation in flow during the cardiac cycle compared to copulsation mode. 
However, the arterial pulse pressure with counter pulsation LVAD RPM 
modulation at high RPM modulation amplitudes (1100 RPM, 800 RPM) was still 
higher than observed with no LVAD RPM modulation. Altering the timing of 
synchronous LVAD RPM modulation from counter pulsation to co-pulsation mode 
resulted in increased pulse pressure, EEP, and SHE. However, asynchronous 
modulation produced the highest ranges of MAP, EEP, and SHE, as predicted by 
the computer simulation results. Asynchronous LVAD RPM modulation resulted 
in beat-to-beat variances in pressures and volumes of the native ventricle. These 
variations in beat-to-beat pressures and volumes may be counterproductive for 
reversal of heart failure and ultimate recovery of the patient for device 





It should be noted that retrograde flows also increase aortic pressure pulsatility, it 
should be avoided as it may increase device related hemolysis, LV volumes and 
LV wall stresses [57, 69]. Retrograde flow was present in this study during 
asynchronous LVAD modulation with high RPM modulation of 1100 RPM. This 
resulted in prolonged periods of the LVAD operating at its baseline of 1800 RPM. 
Additionally, this occurred during co-pulsation LVAD RPM modulation at 
2900±1100 RPM.  
 
A normal human heart produces a peak flow rate of 30-35 L/min and minimum 
flow of ~0 L/min, resulting in an aortic pressure pulsatility of approximately 40 
mmHg. A failing heart produces a peak flow rate of 20-25 L/min, but still results in 
an aortic pressure pulsatility of 30-35 mmHg due to higher vascular impedance 
[4]. Current LVAD technology is limited in the maximum achievable flows. In this 
study, peak LVAD flows of 8.5 L/min occurred during co-pulsation LVAD RPM 
modulation at 2900±1100 RPM and asynchronous LVAD RPM at 3200±800RPM 
with a period of 1.6 seconds. The current LVAD technology limitations restrict the 
maximum achievable pressure pulse, ventricular unloading, and modulation 
amplitude. With technological improvements, higher flows and RPM modulation 
amplitudes may allow for increased pulse pressure, reduced LVEW, and 






There are several limitations associated with the mock circulation model. For 
instance, the mock circulation cannot mimic neurohumoral responses, tissue 
remodeling, activation of regulatory proteins, or changes in genetic phenotype, 
but it can demonstrate feasibility of concepts and allow for design testing and 
improvements without the use of chronic living animal models, which allow for 
nuerohumoral responses, tissue remodeling, activation of regulatory proteins, 
and changes in genetic phenotype. Furthermore, mock circulation models use 
lump total systemic compliance which is significantly lower than aortic 
compliance[58]. The lower value of lumped systemic compliance would artificially 
augment pressure pulsatility, which may lead to reports of up to 61 mmHg of 
pressure pulsatility with less than 5 L/min of flow pulsatility [24]. In our study, we 
minimized this effect by having a large compliance  element with low flow 
resistance near the aortic root. This enabled a close approximation of physiologic 
aortic compliance and approximately 20 mmHg pressure pulsatility with 
synchronous LVAD modulation amplitudes of ~9 L/min, as predicted by computer 
simulation results. Similarly, animal models have significantly different aortic and 
arterial compliance values than humans [59]. These altered compliance values 
would lead to an inaccurate estimation of aortic pressure pulsatility, Figures 9, 




reduction in left ventricular peak pressures due to pneumatic/hydraulic drivers, 
which may lead to inaccurate estimation of LVEW.  In this study, three levels of 
ventricular contractility were used to mimic the reduced ventricular contractility. 
However, in this mock circulation study, fixed ventricular contractility may have 
resulted in higher calculated LVEW during counter pulsation LVAD RPM 
modulation which resulted in lower stroke volumes than co-pulsation LVAD RPM 
modulation but similar peak pressures.  
 
The computer model assumed ideal valves that open and close instantaneously, 
Newtonian blood, a constant diastolic ventricular compliance, does not account 
for inertial or gravitational effects, and the effects of wave reflection. The mock 
circulation model overcame these limitations as it accounted for variable diastolic 
ventricular compliance, inertial and gravitational effects, and the effects of wave 
reflection. Further, the mock circulation model used mechanical valves which 
model realistic valve opening and closing times. However, mechanical valves 
resulted in ringing during valve closure, which was filtered out during analysis. 
The animal experiments had native valves with realistic opening and closing 
without any valve ringing. The mock circulation used a mixture of plasmalyte 
solution and water, which is also a Newtonian fluid. However, at these high 
velocities, blood acts as a Newtonian fluid. The ventricular contractility in the 




tried to overcome this limitation by manually reducing the ventricular contractility. 
However, a more accurate ventricular volume dependent contractility was 
achieved in the computer simulation and animal experiments.  
 
Modulation of CF LVAD RPM would increase power consumption and bearing 
wear which may be minimized in using the HeartWare HVAD, a magnetically 
suspended CF LVAD. This study only reports the results using the HeartWare 
centrifugal HVAD LVAD. Pump inertia, friction, and loading profiles will vary from 
pump to pump and affect the relationship between RPM modulation and flow 
modulation and the resulting power consumption. The rpm modulation needed to 
achieve specific levels of flow modulation will be different for each device which 
can be calculated from the pump models.  
 
The mock circulation only represents systemic circulation as it was only intended 
to test a LVAD and not a right ventricular assist device or bi-ventricular assist 
device. To test flow modulation to these other devices, a pulmonary circulation 
must be added. The instrumentation used to record hemodynamics possesses 
inherent errors (pressure error = ±1mmHg, flow errors = ±0.5L/min) which the 
authors attempted to minimize by using GLP compliant test equipment and 





Comparison of Computer Simulation and Mock Circulation Results 
 
Both computer simulation and mock circulation experiments showed similar 
results when comparing non-modulation, synchronous modulation, and 
asynchronous modulated LVAD flow/RPM (Figures 9, 20). However, 
Inconsistencies were present during comparisons of computer simulation [44] 
and mock circulation results. Specifically, in the computer simulation, co-
pulsation of LVAD flow resulted in increased LVEW while mock circulation results 
showed a decrease in LVEW from CF baselines. Additionally, counter pulsation 
LVAD flow modulation produced increased pulse pressures in the computer 
simulation and decreased pulse pressures in the mock circulation as compared 
to non-modulated LVAD flow. It is important to note differences in the study 
design of the experiments and specifically the LVAD used in each, which may 
have resulted in the described inconsistencies. In the computer simulation the 
LVAD was modeled as a flow source in order to allow for back calculation for 
various pump specific RPM for individual LVAD to produce simulated flows. 
Pump inertia, friction, and loading profiles will vary from pump to pump and affect 
the relationship between rpm/power modulation and flow modulation. The 
computer simulation was designed to be applicable to any pump that could 
produce the constructed flow waveforms under the pressure conditions. However, 




various pumps would have differing resistances that were not present in the flow 
source. Conversely, in the mock loop studies the ventricle ejected through the 
pump. This difference may have resulted in the computer simulation showing 
increase in LVEW during co-pulsation LVAD flow modulation and the mock loop 
study showing a decrease in LVEW during co-pulsation LVAD RPM modulation.  
 
Counterpulsing by modulating LVAD RPM resulted in smaller variation in flow as 
the native ventricular contraction caused a high flow during systole while high 
LVAD RPM increased flow during diastole, leading to a smaller variation in flow 
during the cardiac cycle compared to copulsation mode. This, combined with 
ejection through the aortic valve due to higher mock ventricular contractility may 
have produced the diminished pulse pressure present during counter pulsation 
LVAD RPM/flow modulation in the mock circulation experiments as compared to 
the computer simulations. In the mock circulation study, the ventricle ejected 
volume while the LVAD was operating in a low speed resulting in a much higher 
minimum aortic pressure than seen in the computer simulation. Additionally, in-
vitro mock circulation systems typically underestimate the reduction in left 
ventricular peak pressures due to pneumatic/hydraulic drivers, which may lead to 
inaccurate estimation of LVEW and in this instance resulted in lower calculated 





The computer simulation maintained precise control over mean, peak, and 
minimum LVAD flows. Conversely, the HVAD used in the mock loop studies 
could only control RPM and not specific flows. In mock circulation studies, co-
pulsation and counter pulsation LVAD RPM modulation resulted in differing mean 
LVAD flow rates. In this case the two modulation timings could not be directly 
compared as they were in the computer simulation and may have resulted in 
varying degrees of change from non-modulated LVAD flow/rpm baselines. 
Furthermore, the computer simulation allowed for multiple pulse widths which 
enabled pure co-pulsation and counter pulsation LVAD flow modulation. The 
HVAD controller could only produce a 50% pulse width due to programming 
limitations and thus was not in “pure” co-pulsation or counter pulsation. Figure 8 
shows in computer simulations that synchronization with a 50% pulse width 
would yield decreased LVEW as compared to 40% pulse width during co-
pulsation and increased LVEW compared to 60% pulse width during counter 
pulsation. Additionally, since  the HVAD controller could not be triggered off of an 
ECG or pressure waveform, the controller was phased in and out of co-pulsation 
and counter pulsation modes by offsetting the LVAD cycle time (0.8 seconds) 
and the beat time (0.795 seconds) by 0.005 seconds. Future iterations of the 


























Computer simulation and mock circulatory model testing are important steps in 
the development of LVAD control strategies. However, they cannot replace in-
vivo animal testing and clinical trials as they cannot mimic neurohumoral 
responses, tissue remodeling, activation of regulatory proteins, or changes in 
genetic phenotype. Animal model testing is an important step in proving device 
and control strategy safety for the ultimate advancement to clinical therapy. 
However, normal animal models do not adequately simulate a human in heart 
failure to allow for efficacy testing. Thus, we present preliminary findings of LVAD 
RPM modulation in an ischemic bovine heart failure model and normal calf.  We 
hypothesize that modulation of LVAD RPM will increase arterial pressure 
pulsatility and alter left ventricular pressures, volumes, and workloads. Further, 
the effect on the ventricle will be dependent on timing. We hypothesized that 
modulation of LVAD RPM will increase arterial pressure pulsatility and enable 
alteration of left ventricular pressures, volumes, and workloads. Further, we 
hypothesized that the magnitude of these effects on the native ventricle will be 




was to investigate the effects of LVAD RPM modulation on the ventricle and 
vasculature with varying modulation amplitudes, widths, and frequencies and 
compare the results to computer simulation and mock circulation results. 
 




Male, mixed-breed calves (n=2) were used in this study.  Heart failure was 
induced in the two animals using micro-embolization techniques and implanted 
with HeartWare LVAD 60-days later for LVAD RPM modulation testing while 
under anesthesia. The HeartWare HVAD centrifugal LVAD was used in this study. 
All animals received humane care and were handled in accordance with National 
Institutes of Health and the University of Louisville animal care committee 
guidelines.  All experimental procedures were approved by the University of 




The LVAD controller was programmed to modulate LVAD RPM by engineers at 




animal studies, the controller modulated the LVAD speed up and down by user 
given RPM steps around a user defined base speed. The HeartWare HVAD has 
pump defined speed limits of 1800 – 4000 RPM. The controller allowed for 
modulation periods with a minimum of 0.20 seconds in 0.01 second increases. 
The pump would be in high RPM (base RPM plus high RPM modulation 
amplitude) for the high RPM period and the low RPM (base RPM minus low RPM 
modulation amplitude) for the low RPM period. For example, if a high RPM 
period of 0.35 sec was chosen with an 1100 RPM modulation amplitude, a low 
RPM period of 0.4 sec with an 800 RPM modulation amplitude, and a base RPM 
of 2900, the pump would operate at 2100 RPM for 0.4 seconds followed by 4000 
RPM for 0.35 seconds and then repeat the cycle. The complete modulation cycle 
would take 0.75 seconds. The controller also allowed for ECG-triggered 
modulation. Once the ECG signal went above a user defined threshold, the 
LVAD would operate through the modulation cycle and then wait for the next 
instance where the ECG threshold was exceeded before operating through the 











Sixty-days after micro-embolization (n=2) a terminal study was performed to 
measure the acute hemodynamic effects of LVAD RPM modulation. Anesthesia 
was induced and maintained in the proper fashion.  The animal was placed on 
the operating table in right lateral recumbency.  Fluid-filled arterial and venous 
catheters were placed in the left carotid artery and jugular vein for blood 
sampling.  A left thoracotomy was performed.  Ribs #4 and #5 were 




At the start of the LVAD RPM modulation experiment, a single-tip, high-fidelity 
micromanometer catheter (Millar Instruments, Houston,TX) was placed in the 
aorta and a dual pressure-volume conductance catheter (Millar Instruments, 
Houston, TX) was advanced from the left atrium across the mitral valve into the 
left ventricle for simultaneous measurement of aortic, left atrial, and left 
ventricular blood pressures.  A transit-time ultrasonic flow probe (Transonics, 




All transducers were pre- and post-calibrated against known physical standards 
to ensure measurement accuracy. Calibration curves for the volume conductance 
catheter were constructed using static and dynamic tests pre- and post-
experiment.  Hemodynamic data were collected at 400Hz, signal conditioned, 
and A/D converted for digital analysis using our GLP compliant data acquisition 
system. 
 
To determine the acute effects of LVAD RPM modulation, pressure and flow 
waveforms were used to derive heart rate, left ventricular end-diastolic pressure, 
left ventricular peak-systolic pressure, ±dP/dt, mean aortic pressure, systolic 




systolic, a standard index of cardiac metabolic demand, pulmonary artery flow as 
an index of cardiac output, and CO normalized to animal weight.  Hemodynamic 
indices were calculated on a beat-to-beat basis for each 30 second data set with 
the Hemodynamic Evaluation and Assessment Research Tool (HEART) program 
developed in Matlab (Version 6.5, MathWorks, Natick, MA).  All analyzed beats in 
each data set (approximately 30 to 50beats/30 second data set) were averaged 




LVAD RPM modulation was tested in two animals. In one animal, no data sets of 
non-modulated flow were taken for comparison. In one animal non-modulated 
LVAD RPM (2900RPM) and counter pulsation LVAD RPM modulation were 
compared (2900±1100RPM) (mean RPM ± modulation RPM).  Mean and 
diastolic coronary flows were increased 24% and 80%, respectively, during 
counter pulsation LVAD RPM modulation. However, systolic coronary flow was 
decreased by 30%. Aortic pulse pressure was increase from 2 mmHg at CF 
LVAD to 15 mmHg at counter pulsation LVAD RPM modulation. However, in 
these two cases, heart rate, mean LAVD flow, and cardiac output were 20% 
greater during LVAD RPM modulation than during non-modulated CF LVAD 




pulsation LVAD RPM modulation as compared to non-modulated LVAD RPM 
(Figure 26).  During asynchronous LVAD RPM modulation, pressures and 
volumes varied on a beat to beat basis and pulse pressure of up to 10 mmHg 





Table 7: Heart rate (HR), stroke volume (SV), cardiac output (CO), mean 
LVAD flow (VADF), left ventricular end diastolic pressure (LVPed), peak 
systolic left ventricular pressure (LVPpks), mean aortic pressure (MAP), 
aortic pulse pressure (AoPpulse), mean coronary flow (CAFmean), mean 
systolic coronary flow (CAFavsys), and mean diastolic coronary flow 
(CAFavdias) for CF LVAD and counter pulsation LVAD RPM modulation 
with same mean VADF.  
 
 
Condition HR SV CO VADF LVPed LVPpks MAP AoPpulse CAFmean CAFavgsys CAFavdias
CF VAD 2900 RPM 70 66 4.6 4.4 8 34 44 2 163 143 163
Counter pulse 2900 + 1100 85 65 5.5 5.3 9 53 41 15 202 100 294





Figure 26: Aortic pressure, left ventricular pressure, LVAD flow, coronary 
artery flow (CAF), ECG, and pressure volume loops for counter pulsation 
LVAD RPM modulation (2900±1100RPM) (mean RPM ± modulation RPM) 







Figure 27: Aortic pressure, left ventricular pressure, left ventricular volume 
for Normal CF LVAD, Synchronous CF LVAD (3200±800RPM), and 
asynchronous CF LVAD (3200±800RPM) (mean RPM ± modulation RPM). 
Synchronous CF LVAD modulation increases AoP Pulsatility while 
maintaining consistent ranges of left ventricular pressure and volumes. 
Asynchronous CF LVAD modulation at 19 BPM increases pulse pressure 












The pilot animal study produced similar results as the computer simulation and 
mock circulation studies in proving that LVAD RPM modulation can reduce left 
ventricular volumes and increase arterial pulse pressure. Additionally, animals 
studied showed increased pressure pulsatility with slow asynchronous LVAD 
RPM modulation.  
 
Unfortunately, the hemodynamic state of the animal cannot be held constant 
through all measurement sets due to changes in medications, deterioration of the 
surgical preparation, loss of blood volume, and other factors. Further, full 
unloading was not always achieved with the calf model as the calf has a 
significantly higher cardiac output compared to humans. Thus, in Figure 26 
synchronous LVAD RPM modulation is only providing partial support, and thus 
results in a higher pulse pressure than non-modulated LVAD flow, which is fully 
unloading the ventricle. Additionally, Figure 27 (a) CF LVAD 3200RPM and (c) 
Asynchronous LVAD 3200±800RPM are from a different animal than (b) 
Synchronous LVAD 3200±800RPM. These data sets were chosen as they were 
the only three cases of full support showing their respective LVAD RPM 
modulation. The initial pilot study is severely limited in its ability to show 




that preliminary findings in an in-vivo animal model produce similar results to 
those seen in computer simulations and mock circulation models.  
 
 
Limitations   
 
Animal models are not as stable of a testing platform as the computer simulation 
and mock circulation studies due to deterioration of the surgical preparation, 
effects of drugs, and variabilities in heart rates, ventricular contractilities and 
resistances due to physiologic and neurohormonal responses and other 
mechanisms. This results in increased variation between data sets and a 
diminished ability to directly compare data sets, which was minimized by 
collection of several intermediate baselines to facilitate comparisons. The acute 
animal model incorporates neurohumoral responses, and activation of regulatory 
proteins which are absent in the computer simulation and mock circulation 
studies. Animal models have significantly different aortic and arterial compliance 
values than humans [59]. Specifically, the calf model has a significantly higher 
compliance compared to humans. These altered compliance values would lead 
to a lower and inaccurate estimation of aortic pulse pressure due to LVAD 
modulation compared to computer simulation and mock circulation experiments, 





Modulation of CF LVAD RPM increased power consumption and potentially 
increases bearing wear which may be minimized in using the HeartWare HVAD, 
a magnetically suspended CF LVAD. This study only reports the results using the 
HeartWare centrifugal HVAD LVAD. Pump inertia, friction, and loading profiles 
will vary from pump to pump and affect the relationship between RPM modulation 
and flow modulation and the resulting power consumption. However the 
principles of RPM/flow modulation and increasing vasculature pulsatility is pump 
independent as evinced by the computer simulation study. The instrumentation 
used to record hemodynamics possesses inherent errors (pressure error = 
±1mmHg, flow errors = ±0.5L/min) which the authors attempted to minimize by 

























The results of this study establish that arterial pulsatility and ventricular work can 
be affected significantly by modulating CF LVAD flow. Arterial and ventricular 
hemodynamic waveforms were altered by varying the timing, amplitude, and 
width of the LVAD flow modulation pulse for the same average LVAD flow rates. 
Importantly, a range of LVEW and CoF values can be obtained for the same 
mean CF LVAD flow rate by altering the LVAD flow modulation without 
significantly affecting end-organ perfusion. Thus, these LVAD flow/RPM 
modulations may reduce the incidence of adverse events associated with the CF 
LVAD therapy by increasing vascular pulsatility and reducing vascular 
impedance. Further, these methods of LVAD flow/RPM modulation may enable 
tailored unloading of the native ventricle to provide rest and rehabilitation 
(maximal unloading to rest followed by gradual reloading to wean), which may 
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